NCT05295589 2023-09-26Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyNational Cancer Institute (NCI)Phase 2 Withdrawn